Aspire Biopharma Holdings, Inc.
ASBP
$5.17
-$0.35-6.34%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 217.08% | 350.55% | 417.36% | 427.03% | 737.99% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 177.62% | 432.93% | 725.49% | 516.97% | 775.10% |
| Operating Income | -176.98% | -432.05% | -725.49% | -516.97% | -775.10% |
| Income Before Tax | -514.82% | -759.50% | -1,944.69% | -6,801.00% | -903.54% |
| Income Tax Expenses | -- | -- | -- | -- | -100.00% |
| Earnings from Continuing Operations | -514.82% | -755.52% | -1,944.69% | -6,801.00% | -897.01% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -514.82% | -755.52% | -1,944.69% | -6,801.00% | -897.01% |
| EBIT | -176.98% | -432.05% | -725.49% | -516.97% | -775.10% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -66.01% | -376.85% | -1,043.68% | -4,927.50% | -16,645,750.00% |
| Normalized Basic EPS | -66.01% | -379.10% | -833.50% | -470.86% | -20,807,200.00% |
| EPS Diluted | -66.01% | -376.85% | -1,043.68% | -4,927.50% | -16,645,750.00% |
| Normalized Diluted EPS | -66.01% | -379.10% | -833.50% | -470.86% | -20,807,200.00% |
| Average Basic Shares Outstanding | 270.43% | 79.57% | 78.70% | 37.39% | -99.99% |
| Average Diluted Shares Outstanding | 270.43% | 79.57% | 78.70% | 37.39% | -99.99% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |